EFSA opened on 23.02.2023 a public consultation on the RAR for flurochloridone.
3rd March 2023
Public consultation flurochloridone
03March
13th October 2021
EFSA consultation ED assessment aluminium ammonium sulphate
13October
EFSA opened on 12.10.2021 a public consultation on an update of the RAR of aluminium ammonium sulphate.
22nd December 2020
Commission explains plans for classification endocrine disruptors
22December
On 22.12.2020 the Commission answered a question from MEP Hélène Laporte about endocrine disruptors, providing a good insight in the Commission’s plans with regard to classification.
9th November 2020
EFSA consultation clofentezine: ED & Art.4.7
09November
On 06.11.2020 EFSA opened a public consultation on the updated RAR for clofentezine.
27th October 2020
Draft endocrine data requirements BPR
27October
A draft Regulation, amending the data requirements for the Biocidal Products Regulation, entered the scrutiny procedure of the European Parliament.
8th October 2020
HEAL & Belgian Health Insurance Funds joint symposium on Endocrine Disruptors
08October
HEAL and the Belgian Independent Health Insurance Funds organise a joint symposium on endocrine disruptors.
19th September 2020
Client Earth on Endocrine Disruptors
19September
Environmental Organisation Client Earth published a report on endocrine disrupting chemicals.
8th September 2020
RoQ 07.09.2020
08September
daminozide, rapeseed oil, flumioxazin, glyphosate
18th August 2020
TBT notification etoxazole
18August
The European Commission notified to the WTO/TBT its intention to restrict the (renewed) approval of etoxazole.
28th July 2020
benthiavalicarb ED & Art. 4.7 consultation
28July
EFSA opened on 27.07.2020 a public consultation on benthiavalicarb, regarding the assessments following the stop-the-clock for Endocrine Disruption assessment.
6th May 2020
RoQ 05.05.2020
06May
NOTE: this is the first of the “EFSA RoQ updates”. Please note that for some alerts the change is indicated as “new document(s) uploaded”. This is to be considered as a...
8th April 2020
Commission factual summary report on endocrine disruptors
08April
On 07.04.2020 a “Factual Summary Report” appeared in the EurLex website, on the Public Consultation in the context of the Fitness Check of the EU legislation with regard to Endocrine...
8th April 2020
EFSA report on recurring toxicology issues
On 06.04.2020 EFSA published a Technical Report (EN-1837) on general recurring issues in mammalian toxicology.
19th March 2020
HEAL targets 3 fungicides in France
19March
On 06.03.2020 HEAL sent an open letter to the French Minister of Agriculture, and to the Director of ANSES, demanding action with regard to the approvals of 3 fungicide substances.
17th February 2020
Consultation biocides data requirements, endocrine data
17February
On 13.02.2020 the Commission opened a consultation on proposed amendments to Annexes II and III of the Biocides Regulation.
17th December 2019
EFSA Working Group on Adverse Outcome Pathways
17December
On 04.12.2019 EFSA published the minutes of the first meeting of the Working Group on “Development of adverse outcome pathways relevant for the identification of substances having endocrine...
7th November 2019
Forum on Endocrine Disruptors
07November
On 08.11.2019 the European Commission’s DG Environment will be holding its first annual Forum on Endocrine Disruptors.
10th October 2019
EP adopts resolution on draft Regulation on extension of chlorotoluron and 28 other substances
10October
On 10.10.2019 the European Parliament adopted its resolution on the draft Commission Regulation extending the approval periods of chlorotoluron and 28 other substances.
1st October 2019
Motion for a resolution on Regulation on the extension of the approval of 29 substances
01October
On 01.10.2019 the European Parliament published a motion for a resolution on the draft Regulation on the extension of chlorotoluron and 28 other substances.
24th September 2019
Ziram renewal further delayed by Endrocrine Disruption assessment
24September
On 24.9.2019 the EFSA Register of Questions was updated with regard to an additional data request for ziram on endocrine disrupting effects.